Lexicon Pharma (LXRX): Physician Feedback Increases Confidence - H.C. Wainwright

H.C. Wainwright analyst, Shaunak Deepak, reiterated his Buy rating on shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) after physician feedback leaves him more confident in telotristat prospects in Europe.

If telotristat is approved in Europe, the analyst believes that there could be considerable interest among physicians. At ESMO he attended an industry symposium on carcinoid syndrome treatment and a poster discussion session for the integrated telotristat Phase 3 safety data. During these events, he spoke with four European investigators involved in telotristat clinical trials.

Based on feedback, he is increasing peak European telotristat sales estimates from $180M to $310M in 2023.

No change to the price target of $26.

For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.

Shares of Lexicon Pharmaceuticals closed at $16.70 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Uber Inc. (UBER) PT Raised to $96 at Tigress Financial Partners
• Piper Sandler Downgrades Southwestern Energy (SWN) to Neutral